Transperineal in vivo fluence-rate dosimetry in the canine prostate during SnET2-mediated PDT.
Advances in photodynamic therapy (PDT) treatment for prostate cancer can be achieved either by improving selectivity of the photosensitizer towards prostate gland tissue or improving the dosimetry by means of individualized treatment planning using currently available photosensitizers. The latter approach requires the ability to measure, among other parameters, the fluence rate at different positions within the prostate and the ability to derive the tissue optical properties. Here fibre optic probes are presented capable of measuring the fluence rate throughout large tissue volumes and a method to derive the tissue optical properties for different volumes of the prostate. The responsivity of the sensors is sufficient to detect a fluence rate of 0.1 mW cm(-2). The effective attenuation coefficient in the canine prostate at 660 nm is higher at the capsule (2.15+/-0.19 cm(-1)) than in proximity of the urethra (1.84+/-0.36 cm(-1)). Significant spatial and temporal intra- and inter-canine variability in the tissue optical properties was noted, highlighting the need for individualized monitoring of the fluence rate for improved dosimetry.
Lilge
Lothar
L
Ontario Cancer Institute, Princess Margaret Hospital, Toronto, ON, Canada. llilge@uhnres.utoronto.ca
Pomerleau-Dalcourt
Natalie
N
Douplik
Alexander
A
Selman
Steven H
SH
Keck
Rick W
RW
Szkudlarek
Maria
M
Pestka
Maciej
M
Jankun
Jerzy
J
D000465:Algorithms; D000818:Animals; D004285:Dogs; D008027:Light; D008297:Male; D015233:Models, Statistical; D010778:Photochemotherapy / Q000379:methods*; D017319:Photosensitizing Agents / Q000494:pharmacology; D011166:Porphyrins / Q000494:pharmacology; D011467:Prostate / Q000528:radiation effects*; D011471:Prostatic Neoplasms / Q000473:pathology / Q000532:radiotherapy*; D011874:Radiometry / Q000379:methods*; D013997:Time Factors
D017319:Photosensitizing Agents; D011166:Porphyrins; C063166:tin etiopurpurin